Tunable cytotoxic aptamer–drug conjugates for the treatment of prostate cancer

Bethany Powell Gray,Linsley Kelly,Douglas P. Ahrens,Ashley P. Barry,Christina Kratschmer,Matthew Levy,Bruce A. Sullenger

DOI: https://doi.org/10.1073/pnas.1717705115

IF: 11.1

2018-04-16

Proceedings of the National Academy of Sciences

Abstract:Significance As prostate cancer is the second leading cause of cancer-related death among men in the United States, an unmet medical need exists for therapies that eliminate prostate tumors while preventing toxicity in normal tissue. Recently, such tumor-targeting therapies have gained Food and Drug Administration approval in the form of antibody drug conjugates. However, a need exists for new tumor-targeting therapies that are easier to manipulate and synthesize. By selecting for RNA ligands that internalize into prostate cancer cells but not normal prostate cells, we developed another class of targeted agents. We demonstrate that the E3 RNA selectively internalizes into prostate cancer cells and that E3 highly toxic drug conjugates are potent anti-tumor agents.